Jan 14, 2025 08:45AM
Jan 9, 2023 08:05AM
Jan 9, 2023 08:00AM
Jul 19, 2021 07:00AM
Jun 9, 2021 07:00AM
Jun 4, 2021 09:00AM
Apr 28, 2021 12:35PM Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Mar 31, 2021 07:00AM
Mar 30, 2021 07:00AM
Mar 23, 2021 07:00AM
Jan 20, 2021 07:00AM
Dec 7, 2020 07:00AM
Nov 16, 2020 07:00AM
Nov 12, 2020 08:00AM Provectus Biopharmaceuticals Announces Acceptance of PV-10® Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020
Oct 15, 2020 08:00AM
Oct 5, 2020 08:00AM
Sep 21, 2020 02:05PM
Sep 21, 2020 12:45PM
Sep 17, 2020 07:00AM
Sep 17, 2020 06:00AM
Aug 13, 2020 08:00AM Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Oral Administration of Rose Bengal Disodium for Cancer Treatment
Jul 22, 2020 08:00AM
Jun 22, 2020 07:30AM
Jun 9, 2020 09:00AM
Jun 1, 2020 09:00AM
Jun 1, 2020 07:06AM
Jun 1, 2020 07:00AM
May 18, 2020 09:00AM Provectus Announces PV-10® STING Agonist Abstract at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II
Apr 29, 2020 04:30PM
Apr 16, 2020 05:30PM
Mar 17, 2020 08:00AM
Dec 12, 2019 08:00AM
Dec 2, 2019 08:00AM
Nov 21, 2019 10:19AM
Nov 21, 2019 09:00AM Provectus Announces Presentation of Updated Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Naïve Advanced Melanoma at SMR 2019 Congress
Oct 24, 2019 07:00AM
Sep 24, 2019 09:00AM
Sep 11, 2019 07:00AM
Aug 27, 2019 09:00AM
Jul 29, 2019 08:00AM
Jul 15, 2019 08:00AM
Jul 8, 2019 08:00AM Provectus Provides Update on GI Tumor Program for Investigational Cancer Drug PV-10
Jun 3, 2019 04:05PM
Jun 3, 2019 09:10AM
Jun 3, 2019 09:05AM
May 9, 2019 08:05AM
Apr 17, 2019 04:05PM
Mar 25, 2019 08:00AM
Mar 21, 2019 08:00AM Provectus Provides Update on Metastatic Uveal Melanoma Clinical Development Program for Investigational Drug PV-10
Feb 19, 2019 07:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All